Form 4: Chromocell Therapeutics Director Acquires Restricted Stock Units
SEC Form 4
Todd C Davis, a director of Chromocell Therapeutics Corp, acquired 128,977 restricted stock units at an exercise price of $1.30 per share on June 14, 2024.
Summary
- On June 14, 2024, Todd C Davis, a director of Chromocell Therapeutics Corp, was granted 128,977 restricted stock units.
- The exercise price is $1.30 per share.
- The restricted stock units vest on a quarterly basis over two years.
- Following the transaction, Davis directly owns 213,701 shares of common stock.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a routine disclosure of stock unit grants.
Industry Context
This is a standard disclosure related to executive compensation and insider transactions, common in the biotech industry.
Key Dates
| Date | Description |
|---|---|
| 06/14/2024 | Date of transaction: Grant of 128,977 restricted stock units at $1.30 per share. |
| 06/18/2024 | Date of signature on the Form 4 filing. |
| 06/14/2034 | Expiration date of the restricted stock units. |
Keywords
Chromocell Therapeutics, restricted stock units, Form 4, director, Davis, CHRO, acquisition
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.